摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl 4-(benzo[d]thiazol-2-ylthio)piperidine-1-carboxylate | 333985-92-5

中文名称
——
中文别名
——
英文名称
tert-butyl 4-(benzo[d]thiazol-2-ylthio)piperidine-1-carboxylate
英文别名
1-tert-butoxycarbonyl-4-(2-benzothiazolylthio)piperidine;4-(Benzothiazol-2-ylsulfanyl)-piperidine-1-carboxylic acid tert-butyl ester;tert-butyl 4-(1,3-benzothiazol-2-ylsulfanyl)piperidine-1-carboxylate
tert-butyl 4-(benzo[d]thiazol-2-ylthio)piperidine-1-carboxylate化学式
CAS
333985-92-5
化学式
C17H22N2O2S2
mdl
——
分子量
350.506
InChiKey
ZFOTXJHZLYPECJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    484.2±55.0 °C(Predicted)
  • 密度:
    1.26±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.5
  • 重原子数:
    23
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.53
  • 拓扑面积:
    96
  • 氢给体数:
    0
  • 氢受体数:
    5

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Polarity Umpolung Strategy for the Radical Alkylation of Alkenes
    作者:Jige Liu、Shuo Wu、Jiajia Yu、Chenxi Lu、Zhen Wu、Xinxin Wu、Xiao‐Song Xue、Chen Zhu
    DOI:10.1002/anie.201915837
    日期:2020.5.18
    Free radical-mediated alkylation of general alkenes is a challenging and largely unmet goal. Herein, we disclose a conceptually novel "polarity umpolung" strategy for radical alkylation of alkenes using a portfolio of easily-accessed, dual-function alkylating reagents. This is achieved by substituting inherently nucleophilic alkyl radicals with electrophilic sulfone-decorated surrogates, thus inverting
    自由基介导的一般烯烃的烷基化是一个具有挑战性且很大程度上未实现的目标。在这里,我们公开了一种概念上新颖的“极性化学极化”策略,该策略使用易于获得的双功能烷基化试剂进行烯烃的自由基烷基化。这可以通过用亲电砜修饰的替代物取代固有的亲核烷基自由基,从而改变通常的反应方式。随着烷基化,额外的杂芳基或肟基通过连续的对接和迁移过程同时并入烯烃,从而产生有价值的产品。该反应在温和条件下显示出宽泛的官能团耐受性。该协议为复杂的天然产物和含有烯烃部分的药物分子的后期修饰打开了新的前景。
  • Cyclic amine compounds as CCR5 antagonists
    申请人:Takeda Chemical Industries, Ltd.
    公开号:US06562978B1
    公开(公告)日:2003-05-13
    A compound of formula (I) (wherein R1 is a hydrogen atom, a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, R2 is a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, or R1 and R2 may combine to each other together with A to form a heterocyclic group which may be substituted; A is N or N+—R5.Y−(R5 is a hydrocarbon group; Y− is a counter anion); R3 is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; n is 0 or 1; R4 is a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, an alkoxy group which may be substituted, an aryloxy group which may be substituted, or an amino group which may be substituted, E is a divalent aliphatic hydrocarbon group which may be substituted by group(s) other than oxo; G1 is a bond, CO or SO2; G2 is CO, SO2, NHCO, CONH or OCO; J is methine or a nitrogen atom; and each of Q and R is a bond or a divalent C1-3 aliphatic hydrocarbon which may be substituted; provided that J is methine when G2 is OCO, that one of Q and R is not a bond when the other is a bond and that each of Q and R is not substituted by oxo group(s) when G1 is a bond) or a salt thereof has a potent CCR5 antagonistic activity and can be advantageously used for the treatment or prevention of infectious disease of various HIV in human (e.g. AIDS).
    式(I)的化合物(其中R1是氢原子,可能被取代的碳氢基团,可能被取代的非芳香杂环基团,R2是可能被取代的碳氢基团,可能被取代的非芳香杂环基团,或R1和R2可以彼此结合与A一起形成可能被取代的杂环基团;A是N或N+—R5.Y−(R5是碳氢基团;Y−是一个对离子);R3是可能被取代的环烃基团或可能被取代的杂环基团;n为0或1;R4是氢原子,可能被取代的碳氢基团,可能被取代的杂环基团,可能被取代的烷氧基团,可能被取代的芳基氧基团,或可能被取代的氨基团;E是可能被除氧以外的基团取代的二价脂肪族碳氢基团;G1是键,CO或SO2;G2是CO,SO2,NHCO,CONH或OCO;J是亚甲基或氮原子;Q和R中的每一个是键或可能被取代的二价C1-3脂肪族碳氢基团;条件是当G2为OCO时J为亚甲基,当另一个为键时Q和R中的一个不是键,当G1为键时Q和R中的每一个都不被氧基取代)或其盐具有强大的CCR5拮抗活性,并可优势用于治疗或预防人类体内各种HIV引起的传染病(例如艾滋病)。
  • [EN] CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS<br/>[FR] COMPOSES D'AMINE CYCLIQUE UTILISES COMME ANTAGONISTES DE CCR5
    申请人:TAKEDA CHEMICAL INDUSTRIES LTD
    公开号:WO2001025200A1
    公开(公告)日:2001-04-12
    A compound of formula (I) (wherein R1 is a hydrogen atom, a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, R2 is a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, or R?1 and R2¿ may combine to each other together with A to form a heterocyclic group which may be substituted; A is N or N?+-R5 •Y-(R5¿ is a hydrocarbon group; Y- is a counter anion); R3 is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; n is 0 or 1; R4 is a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, an alkoxy group which may be substituted, an aryloxy group which may be substituted, or an amino group which may be substituted, E is a divalent aliphatic hydrocarbon group which may be substituted by group(s) other than oxo; G1 is a bond, CO or SO¿2; G?2 is CO, SO¿2?, NHCO, CONH or OCO; J is methine or a nitrogen atom; and each of Q and R is a bond or a divalent C1-3 aliphatic hydrocarbon which may be substituted; provided that J is methine when G2 is OCO, that one of Q and R is not a bond when the other is a bond and that each of Q and R is not substituted by oxo group(s) when G?1¿ is a bond) or a salt thereof has a potent CCR5 antagonistic activity and can be advantageously used for the treatment or prevention of infectious disease of various HIV in human (e.g. AIDS).
    化合物式为(I)(其中R1是氢原子,可被取代的碳氢基团,可被取代的非芳香杂环基团,R2是可被取代的碳氢基团,可被取代的非芳香杂环基团,或R1和R2可以与A一起结合形成可被取代的杂环基团;A是N或N+ -R5 • Y-(R5是碳氢基团;Y-是反离子);R3是可被取代的环烃基团或可被取代的杂环基团;n为0或1;R4是氢原子,可被取代的碳氢基团,可被取代的杂环基团,可被取代的烷氧基,可被取代的芳氧基,或可被取代的氨基,E是可被除氧基以外的基取代的二价脂肪烃基团;G1是键,CO或SO2;G2是CO,SO2,NHCO,CONH或OCO;J是甲基或氮原子;Q和R中的每一个都是一个键或一个可被取代的二价C1-3脂肪基团;前提是当G2是OCO时,J是甲基,当另一个是键时,其中一个不是键,当G1是键时,Q和R中的每一个都没有被氧基团取代)或其盐具有强效的CCR5拮抗活性,并可用于人类各种HIV感染疾病(例如艾滋病)的治疗或预防。
  • 巯基苯并噻唑脲类化合物、药物制剂及制备方法与应用
    申请人:绍兴市上虞区武汉理工大学高等研究院
    公开号:CN114524780A
    公开(公告)日:2022-05-24
    本发明公开了一种巯基苯并噻唑脲类化合物、药物制剂及制备方法与应用,该巯基苯并噻唑脲类化合物具有良好的抗金黄色葡萄球菌活性,在金黄色葡萄球菌感染的治疗中体现出良好的应用前景并体现了良好的应用潜力,并且制备工艺简单、操作方便。
  • Metal-free radical difunctionalization of ethylene
    作者:Jiajia Yu、Xu Zhang、Xinxin Wu、Tao Liu、Zhi-Qi Zhang、Jie Wu、Chen Zhu
    DOI:10.1016/j.chempr.2022.10.020
    日期:2023.2
    finds limited applications in fine chemical synthesis, resulting in molecules of modest complexity. Ethylene difunctionalization allows for the synthesis of much more complex chemicals, but it is rare and almost always relies on transition-metal catalysis. Herein, we report an unprecedented metal-free radical difunctionalization of ethylene through a functional group migration strategy. The use of sulfone-based
    由于其简单性,乙烯作为最丰富的有机原料,仅在精细化学合成中得到有限的应用,导致分子的复杂性适中。乙烯双官能化可以合成更复杂的化学品,但这种情况很少见,而且几乎总是依赖于过渡金属催化。在此,我们通过官能团迁移策略报告了前所未有的乙烯金属自由基双官能化。使用基于砜的双功能试剂可以在温和条件下以高度选择性的方式直接获得各种二杂芳基化化合物。分子内官能团迁移引起的自由基极性和动力学偏好的精确调节保证了级联三键形成过程的成功可控。
查看更多

同类化合物

(1Z)-1-(3-乙基-5-羟基-2(3H)-苯并噻唑基)-2-丙酮 齐拉西酮砜 阳离子蓝NBLH 阳离子荧光黄4GL 锂2-(4-氨基苯基)-5-甲基-1,3-苯并噻唑-7-磺酸酯 铜酸盐(4-),[2-[2-[[2-[3-[[4-氯-6-[乙基[4-[[2-(硫代氧代)乙基]磺酰]苯基]氨基]-1,3,5-三嗪-2-基]氨基]-2-(羟基-kO)-5-硫代苯基]二氮烯基-kN2]苯基甲基]二氮烯基-kN1]-4-硫代苯酸根(6-)-kO]-,(1:4)氢,(SP-4-3)- 铜羟基氟化物 钾2-(4-氨基苯基)-5-甲基-1,3-苯并噻唑-7-磺酸酯 钠3-(2-{(Z)-[3-(3-磺酸丙基)-1,3-苯并噻唑-2(3H)-亚基]甲基}[1]苯并噻吩并[2,3-d][1,3]噻唑-3-鎓-3-基)-1-丙烷磺酸酯 邻氯苯骈噻唑酮 西贝奈迪 螺[3H-1,3-苯并噻唑-2,1'-环戊烷] 螺[3H-1,3-苯并噻唑-2,1'-环己烷] 葡萄属英A 草酸;N-[1-[4-(2-苯基乙基)哌嗪-1-基]丙-2-基]-2-丙-2-基氧基-1,3-苯并噻唑-6-胺 苯酰胺,N-2-苯并噻唑基-4-(苯基甲氧基)- 苯酚,3-[[2-(三苯代甲基)-2H-四唑-5-基]甲基]- 苯胺,N-(3-苯基-2(3H)-苯并噻唑亚基)- 苯碳杂氧杂脒,N-1,2-苯并异噻唑-3-基- 苯甲基2-甲基哌啶-1,2-二羧酸酯 苯并噻唑正离子,2-[3-(1,3-二氢-1,3,3-三甲基-2H-吲哚-2-亚基)-1-丙烯-1-基]-3-乙基-,碘化(1:1) 苯并噻唑正离子,2-[(2-乙氧基-2-羰基乙基)硫代]-3-甲基-,溴化 苯并噻唑啉 苯并噻唑-d4 苯并噻唑-6-腈 苯并噻唑-5-羧酸 苯并噻唑-5-硼酸频哪醇酯 苯并噻唑-4-醛 苯并噻唑-4-乙酸 苯并噻唑-2-磺酸钠 苯并噻唑-2-磺酸 苯并噻唑-2-磺酰氟 苯并噻唑-2-甲醛 苯并噻唑-2-甲酸 苯并噻唑-2-甲基甲胺 苯并噻唑-2-基磺酰氯 苯并噻唑-2-基叠氮化物 苯并噻唑-2-基-邻甲苯-胺 苯并噻唑-2-基-己基-胺 苯并噻唑-2-基-(4-氯-苯基)-胺 苯并噻唑-2-基-(4-氟-苯基)-胺 苯并噻唑-2-基-(4-乙氧基-苯基)-胺 苯并噻唑-2-基-(2-甲氧基-苯基)-胺 苯并噻唑-2-基-(2,6-二甲基-苯基)-胺 苯并噻唑-2-基(对甲苯基)甲醇 苯并噻唑-2-乙酸甲酯 苯并噻唑-2-乙腈 苯并噻唑-2(3H)-酮N2-[1-(吡啶-4-基)乙亚基]腙 苯并噻唑-2 - 丙基 苯并噻唑,6-(3-乙基-2-三氮烯基)-2-甲基-(8CI)